Hepatocellular Carcinoma
Conditions
Keywords
Urea Cream, Sorafenib
Brief summary
Many investigators have studied for prevention and care of Hand-Foot Skin Reaction(HFSR), and urea cream is typical representative. Recent study was performed prevention effect of urea cream for Hand-Foot Skin Reaction(HFSR) on 871 Chinese. But the study did not designed as placebo-control group and it had big defect in double-blinded. Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect of urea cream on Korean patient group.
Detailed description
Sorafenib is multiple tyrosine kinase inhibitor. It blocks path that such as Raf-1, Vascular Endothelial Growth Factor Receptor (VEGFR), Platelet-Drived Growth Factor Receptor-β (PDGFR-β), c-Jit, Flt-3. Sorafenib was known to increase life rate about processed hepatocellular carcinoma. So it is advised as standard treatment for liver cancer patient who has processed Barcelona Clinic Liver Cancer (BCLC) disease period C. Sorafenib related side effect has reported such as fatigue, diarrhea, vomit, nausea, pruritus, depilation, Hand-Foot Skin Reaction(HFSR). Among the symptoms, Hand-Foot Skin Reaction(HFSR) is the most occurrence after using sorafenib and major reason of drug dose de-escalation, it function as decrease anti-cancer effect of sorafenib. It is known for the reason of Hand-Foot Skin Reaction(HFSR) occurrence is caused by tyrosine kinase inhibitive action, and its characteristic symptom is known as keratocyte necrosis, dermal edema, parakeratosis, hyperkeratosis. The level is categorized grade 1,2,3 according to the severity. The result of meta-analysis of 24 clinical trials that contained 6000 patients, Hand-Foot Skin Reaction(HFSR) occured 39% of sorafenib used patients and 9% of total patients had grade 3 Hand-Foot Skin Reaction(HFSR). But prevalence rate on hepatocellular carcinoma patients who used sorafenib is about 51% on Japanese, 45% on Asia-pacific patient (inclusive Korean) and 73.6% on Chinese. Prevalence rate of Hand-Foot Skin Reaction(HFSR) is different from result of each study, but about 50% of sorafenib used patients has had Hand-Foot Skin Reaction(HFSR) generally and Asian has more higher degree of prevalence rate. Therefore, prevent and care of Hand-Foot Skin Reaction(HFSR) on Korean hepatocellular carcinoma patients who used sorafenib is required. Urea cream is typical representative for prevention and care of Hand-Foot Skin Reaction(HFSR). As stability-guaranteed drug, it is relatively cheap, locally affect and has used for psoriasis treatment. Also it is known for curative effacement on Hand-Foot Skin Reaction(HFSR) after use tyrosine kinase inhibitor such as sorafenib, sunitinib. Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect of urea cream on Korean patient group.
Interventions
DRUGUrea Cream 20%
Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
DRUGPlacebos
Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
Sponsors
Hanmi Pharmaceutical Company Limited
Korea University Guro Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patient who was diagnosed with hepatocellular carcinoma, and was accompanied by impossible for radical treatment in disease period or do not reaction for local treatment, and the first time for sorafenib injection. * Standard of hepatocellular carcinoma diagnosis (2014, The Korean Liver Cancer Association) 1. Suitable on hepatocellular carcinoma pathologically 2. Hepatic nodule size over 1 cm on high-risk patients(hepatitis B virus positive, hepatitis C virus positive and liver cirrhosis) that identified by ultrasonography : In the case of suitable on hepatocellular carcinoma on over in one or two more dynamic contrast enhanced CT, dynamic contrast enhanced MRI, or MRI with Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid(Gd-EOB-DTPA) 3. Hepatic nodule size under 1 cm on high-risk patients that identified by ultrasonography : serum Alpha-fetoprotein(AFP) elevated over normal range constantly when hepatitis activity was restrained, and the case of suitable on hepatocellular carcinoma on over in two more the above image diagnoses
Exclusion criteria
* Unsuitable on inclusion criteria * Patient who has had systemic anticancer therapy before (including sorafenib) * Patient who is receiving another treatment to hepatocellular carcinoma recent 3 weeks (allow to local treatment of metastasis lesion only) * Pregnant or Breastfeeding * Urea cream contraindication patient (Acute eczema, Inflammatory dermatopathy and Hypersensitivity on Urea and Methylparaben)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative incidence of Hand-Foot Skin Reaction(HFSR) on each group | 12 weeks treatment | Comparison of cumulative incidence of HFSR between placebo group and urea cream group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of dose reduction or discontinuation of sorafenib due to HFSR on each group | 12 weeks treatment | Comparison of incidence of dose reduction or discontinuation of sorafenib due to HFSR on each group |
| Assessment of Quality Of Life (QOL) | 12 weeks treatment | Assessment of QOL related to HFSR using The Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL) scoring system. HF-QOL instrument comprises a 20-item symptom scale and an 18-item daily activity scale. Each item was scored from 0 (not at all) to 4 (always or extremely). Therefore, the range of score for HF-QoL was from 0 to 152 points. (Ref. Anderson et al. The Oncoligist 2015;20:831-838) |
| Overall survival | 12 weeks treatment | Overall survival of patients |
| Cumulative incidence of severe HFSR on each group | 12 weeks treatment | Comparison of cumulative incidence of severe HFSR (grade 2 or grade 3) between placebo group and urea cream group |
| Other side effect | 12 weeks treatment | The occurrence rate of other side effect excluding HFSR |
| Incidence of HFSR on 2, 4, 8, and 12 weeks on each group | 2, 4, 8, and 12 weeks | Comparison of incidence of HFSR on 2, 4, 8, and 12 weeks between placebo group and urea cream group |
| Tumor response | 12 weeks treatment | Tumor response using mRECIST criteria |
Countries
South Korea
Outcome results
None listed